Headlines about SIGA Technologies (NASDAQ:SIGA) have trended somewhat positive this week, according to Accern Sentiment Analysis. Accern identifies positive and negative media coverage by monitoring more than twenty million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. SIGA Technologies earned a media sentiment score of 0.24 on Accern’s scale. Accern also assigned press coverage about the biotechnology company an impact score of 45.98684224776 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the stock’s share price in the near future.

Shares of SIGA Technologies (NASDAQ SIGA) opened at $4.88 on Monday. SIGA Technologies has a 1-year low of $1.90 and a 1-year high of $5.24.

COPYRIGHT VIOLATION WARNING: “Somewhat Positive Press Coverage Somewhat Unlikely to Affect SIGA Technologies (SIGA) Share Price” was published by Watch List News and is owned by of Watch List News. If you are accessing this piece on another domain, it was stolen and republished in violation of US & international copyright & trademark laws. The original version of this piece can be read at https://www.watchlistnews.com/somewhat-positive-press-coverage-somewhat-unlikely-to-affect-siga-technologies-siga-share-price/1683079.html.

About SIGA Technologies

SIGA Technologies, Inc is engaged in the development and commercialization of solutions for various unmet medical needs and biothreats. The Company’s lead product is TPOXX, an orally administered antiviral drug that targets orthopoxviruses infections. TPOXX is a small-molecule drug delivered to the Strategic Stockpile under the Project BioShield Act of 2004 (Project BioShield).

Insider Buying and Selling by Quarter for SIGA Technologies (NASDAQ:SIGA)

Receive News & Ratings for SIGA Technologies Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SIGA Technologies Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.